(19)
(11) EP 3 826 642 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.06.2025 Bulletin 2025/24

(45) Mention of the grant of the patent:
07.05.2025 Bulletin 2025/19

(21) Application number: 19742218.1

(22) Date of filing: 23.07.2019
(51) International Patent Classification (IPC): 
A61K 31/7048(2006.01)
A61K 45/06(2006.01)
A61P 43/00(2006.01)
 A61K 31/55(2006.01)
A61P 13/12(2006.01)
A61K 9/20(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/7048; A61K 45/06; A61P 13/12; A61P 43/00; A61K 9/2018; A61K 9/2054
 
C-Sets:
  1. A61K 31/7048, A61K 2300/00;
  2. A61K 31/55, A61K 2300/00;
(86) International application number:
PCT/EP2019/069815
(87) International publication number:
WO 2020/020896 (30.01.2020 Gazette 2020/05)

(54)

EMPAGLIFLOZIN FOR USE IN TREATING ALPORT SYNDROME

EMPAGLIFLOZIN ZUR BEHANDLUNG DES ALPORT-SYNDROMS

EMPAGLIFLOZINE POUR SON UTILISATION DANS LE TRAITEMENT DU SYNDROME D'ALPORT

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 25.07.2018 EP 18185598

(43) Date of publication of application:
02.06.2021 Bulletin 2021/22

(73) Proprietor: Boehringer Ingelheim International GmbH
55216 Ingelheim am Rhein (DE)

(72) Inventors:
  • VON EYNATTEN, Maximilian
    55216 INGELHEIM AM RHEIN (DE)
  • GROSS, Oliver
    37085 GOETTINGEN (DE)
  • HAUSKE, Sibylle, Jenny
    55216 INGELHEIM AM RHEIN (DE)


(56) References cited: : 
WO-A1-2014/028059
WO-A2-2016/029027
 WO-A1-2016/014781
   
  • ANONYMOUS: "NOTE FOR GUIDANCE ON THE EVALUATION OF THE PHARMACOKINETICS OF MEDICINAL PRODUCTS IN PATIENTS WITH IMPAIRED RENAL FUNCTION DISCUSSION", CHMP/EWP/225/02, 23 June 2004 (2004-06-23), pages 1 - 11, Retrieved from the Internet <URL:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003123.pdf> [retrieved on 20170608]
  • BOECKHAUS JAN ET AL: "MO1034: Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Alport Syndrome and Fsgs: A Case Series", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 37, no. Supplement_3, 3 May 2022 (2022-05-03), GB, ISSN: 0931-0509, DOI: 10.1093/ndt/gfac089.011
  • GE MENGYUAN ET AL: "Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome", ELIFE, vol. 12, 2 May 2023 (2023-05-02), GB, pages e83353, ISSN: 2050-084X, DOI: 10.7554/eLife.83353
  • BOECKHAUS JAN ET AL: "MO1034: Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Alport Syndrome and Fsgs: A Case Series", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 37, no. Supplement_3, 3 May 2022 (2022-05-03), GB, ISSN: 0931-0509, DOI: 10.1093/ndt/gfac089.011
  • GE MENGYUAN ET AL: "Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome", ELIFE, vol. 12, 2 May 2023 (2023-05-02), GB, pages e83353, ISSN: 2050-084X, DOI: 10.7554/eLife.83353
  • CHRISTOPH WANNER ET AL: "Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes", THE NEW ENGLAND JOURNAL OF MEDICINE, - NEJM -, vol. 375, no. 4, 28 July 2016 (2016-07-28), US, pages 323 - 334, XP055442115, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1515920
  • ROSER TORRA ET AL: "Abstract", NEPHROLOGY DIALYSIS TRANSPLANTATION., vol. 34, no. 8, 13 June 2019 (2019-06-13), GB, pages 1272 - 1279, XP055621058, ISSN: 0931-0509, DOI: 10.1093/ndt/gfz131
  • USHA PANCHAPAKESAN ET AL: "Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells-Renoprotection in Diabetic Nephropathy?", PLOS ONE, vol. 8, no. 2, 4 February 2013 (2013-02-04), pages e54442, XP055119255, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0054442
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).